Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281528
Status:
TERMINATED
Last Update Posted:
2019-11-22
First Post:
2006-01-24
Brief Title:
Weekly vs Every 2 Week vs Every 3 Week Administration of ABI-007 AbraxaneBevacizumab Combination in Metastatic Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 Abraxane in Combination With Bevacizumab in Women With Metastatic Breast Cancer
Status:
TERMINATED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
sufficient mature data to complete a final analysis
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center open-label randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 Abraxane compared to 2-weekly regimen vs the standard 3-weekly infusion All patients will also receive concurrent bevacizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None